Detection and management of nephrotoxicity during drug development

Author： Loghman-Adham Dr Mahmoud Kiu Weber Dr Chek Ing Ciorciaro Dr Cornelia Mann Dr Jessica Meier Dr Matthias

ISSN： 1474-0338

Source： Expert Opinion on Drug Safety, Vol.11, Iss.4, 2012-07, pp. : 581-596

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Nenatal Drug Induced Nephrotoxicity : Old and Next Generation Biomarkers for Early Detection and Management of Neonatal Drug-Induced Nephrotoxicity, with Special Emphasis on uNGAL and on Metabolomics

Current Medicinal Chemistry, Vol. 19, Iss. 27, 2012-09 ,pp. : 4595-4605

Bentham Science Publishers

Access to resources Recommend Favorite

Modelling during drug development

By Balant L.P. Gex-Fabry M.

European Journal of Pharmaceutics and Biopharmaceutics, Vol. 50, Iss. 1, 2000-07 ,pp. : 13-26

Elsevier

Access to resources Recommend Favorite

Drug development for the management of organophosphorus poisoning

By Elsinghorst Paul Wilhelm Worek Franz Thiermann Horst Wille Timo

Expert Opinion on Drug Discovery, Vol. 8, Iss. 12, 2013-12 ,pp. : 1467-1477

Informa Healthcare

Access to resources Recommend Favorite

Evaluating the QT-Liability of a Drug during its Development

By Shah Rashmi R.

Pharmaceutical Medicine, Vol. 22, Iss. 3, 2008-01 ,pp. : 151-164

Adis International

Access to resources Recommend Favorite

Genomic-based biomarkers of drug-induced nephrotoxicity

By Davis John W Kramer Jeffrey A

Expert Opinion on Drug Metabolism and Toxicology, Vol. 2, Iss. 1, 2006-02 ,pp. : 95-101

Informa Healthcare

Access to resources Recommend Favorite